140 related articles for article (PubMed ID: 27583899)
21. Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.
Geybels MS; Zhao S; Wong CJ; Bibikova M; Klotzle B; Wu M; Ostrander EA; Fan JB; Feng Z; Stanford JL
Prostate; 2015 Dec; 75(16):1941-50. PubMed ID: 26383847
[TBL] [Abstract][Full Text] [Related]
22. DNA methylation of METTL7A gene body regulates its transcriptional level in thyroid cancer.
Zhou S; Shen Y; Zheng M; Wang L; Che R; Hu W; Li P
Oncotarget; 2017 May; 8(21):34652-34660. PubMed ID: 28416772
[TBL] [Abstract][Full Text] [Related]
23. Silencing of the maspin gene by promoter hypermethylation in thyroid cancer.
Boltze C; Schneider-Stock R; Quednow C; Hinze R; Mawrin C; Hribaschek A; Roessner A; Hoang-Vu C
Int J Mol Med; 2003 Oct; 12(4):479-84. PubMed ID: 12964023
[TBL] [Abstract][Full Text] [Related]
24. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing.
Xing M; Usadel H; Cohen Y; Tokumaru Y; Guo Z; Westra WB; Tong BC; Tallini G; Udelsman R; Califano JA; Ladenson PW; Sidransky D
Cancer Res; 2003 May; 63(9):2316-21. PubMed ID: 12727856
[TBL] [Abstract][Full Text] [Related]
25. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
27. Demethylation of TMS1 gene sensitizes thyroid cancer cells to TRAIL-induced apoptosis.
Siraj AK; Hussain AR; Al-Rasheed M; Ahmed M; Bavi P; Alsobhi SA; Al-Nuaim A; Uddin S; Al-Kuraya K
J Clin Endocrinol Metab; 2011 Jan; 96(1):E215-24. PubMed ID: 20926535
[TBL] [Abstract][Full Text] [Related]
28. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer.
Guan H; Ji M; Hou P; Liu Z; Wang C; Shan Z; Teng W; Xing M
Cancer; 2008 Jul; 113(2):247-55. PubMed ID: 18470905
[TBL] [Abstract][Full Text] [Related]
29. ZIC1 is a putative tumor suppressor in thyroid cancer by modulating major signaling pathways and transcription factor FOXO3a.
Qiang W; Zhao Y; Yang Q; Liu W; Guan H; Lv S; Ji M; Shi B; Hou P
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1163-72. PubMed ID: 24684457
[TBL] [Abstract][Full Text] [Related]
30. Thyroid Hormone Receptor-β (TRβ) Mediates Runt-Related Transcription Factor 2 (Runx2) Expression in Thyroid Cancer Cells: A Novel Signaling Pathway in Thyroid Cancer.
Carr FE; Tai PW; Barnum MS; Gillis NE; Evans KG; Taber TH; White JH; Tomczak JA; Jaworski DM; Zaidi SK; Lian JB; Stein JL; Stein GS
Endocrinology; 2016 Aug; 157(8):3278-92. PubMed ID: 27253998
[TBL] [Abstract][Full Text] [Related]
31. B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1.
Choi YW; Kim HJ; Kim YH; Park SH; Chwae YJ; Lee J; Soh EY; Kim JH; Park TJ
Exp Mol Med; 2014 Nov; 46(11):e120. PubMed ID: 25378232
[TBL] [Abstract][Full Text] [Related]
32. RIZ1 is epigenetically inactivated by promoter hypermethylation in thyroid carcinoma.
Lal G; Padmanabha L; Smith BJ; Nicholson RM; Howe JR; O'Dorisio MS; Domann FE
Cancer; 2006 Dec; 107(12):2752-9. PubMed ID: 17103461
[TBL] [Abstract][Full Text] [Related]
33. TBX1 Functions as a Tumor Suppressor in Thyroid Cancer Through Inhibiting the Activities of the PI3K/AKT and MAPK/ERK Pathways.
Wang N; Li Y; Wei J; Pu J; Liu R; Yang Q; Guan H; Shi B; Hou P; Ji M
Thyroid; 2019 Mar; 29(3):378-394. PubMed ID: 30543152
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.
van Doorn R; Zoutman WH; Dijkman R; de Menezes RX; Commandeur S; Mulder AA; van der Velden PA; Vermeer MH; Willemze R; Yan PS; Huang TH; Tensen CP
J Clin Oncol; 2005 Jun; 23(17):3886-96. PubMed ID: 15897551
[TBL] [Abstract][Full Text] [Related]
35. Aging related methylation influences the gene expression of key control genes in colorectal cancer and adenoma.
Galamb O; Kalmár A; Barták BK; Patai ÁV; Leiszter K; Péterfia B; Wichmann B; Valcz G; Veres G; Tulassay Z; Molnár B
World J Gastroenterol; 2016 Dec; 22(47):10325-10340. PubMed ID: 28058013
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in molecular biology of thyroid cancer and their clinical implications.
Xing M
Otolaryngol Clin North Am; 2008 Dec; 41(6):1135-46, ix. PubMed ID: 19040974
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer.
Mishra NK; Guda C
Oncotarget; 2017 Apr; 8(17):28990-29012. PubMed ID: 28423671
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic silencing of the NR4A3 tumor suppressor, by aberrant JAK/STAT signaling, predicts prognosis in gastric cancer.
Yeh CM; Chang LY; Lin SH; Chou JL; Hsieh HY; Zeng LH; Chuang SY; Wang HW; Dittner C; Lin CY; Lin JM; Huang YT; Ng EK; Cheng AS; Wu SF; Lin J; Yeh KT; Chan MW
Sci Rep; 2016 Aug; 6():31690. PubMed ID: 27528092
[TBL] [Abstract][Full Text] [Related]
39. [Aberrant methylation of hMLH1 gene promoter in papillary thyroid cancer and its clinical significance].
Lu XX; Ge MH; Ling ZQ; Hu SS; Xu J; Zheng CM; Tan Z; Chen C
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):833-6. PubMed ID: 24447481
[TBL] [Abstract][Full Text] [Related]
40. DNA Methylation-Based Method to Differentiate Malignant from Benign Thyroid Lesions.
Barros-Filho MC; Dos Reis MB; Beltrami CM; de Mello JBH; Marchi FA; Kuasne H; Drigo SA; de Andrade VP; Saieg MA; Pinto CAL; Kowalski LP; Rogatto SR
Thyroid; 2019 Sep; 29(9):1244-1254. PubMed ID: 31328658
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]